D. Medical Receives Registration Certificate From Israel's Ministry of Health For Its Spring Universal Infusion Sets
13 Setembro 2011 - 9:00AM
Marketwired
D. Medical Industries Ltd. (NASDAQ: DMED)(TASE: DMED) ("D. Medical"
or the "Company"), a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery,
announced today that it has received a registration certificate to
market its Spring™ Universal Infusion Sets in Israel.
According to the International Diabetes Federation,
approximately 320 thousand diabetes patients live in Israel. That
number is expected to grow as the population ages.
Efri Argaman, D. Medical's Chief Executive Officer, commented,
"We continue to pursue regulatory clearances for our Spring
Universal Infusion Sets in various target markets in support of our
goal of generating meaningful revenues and reaching positive
margins as quickly as possible. Receiving this approval in our
homeland, a recognized world center for Diabetes research, is
particularly satisfying for us. We are now in the process of
establishing a domestic distribution partnership and expect to be
in a position to make this groundbreaking product commercially
available here soon."
About the Spring Universal Infusion Set
The Spring Universal Infusion Set is compatible with most
insulin pumps currently available on the market. Going beyond the
minimum requirements of subcutaneous drug delivery, the Spring
Universal offers best-in-class features such as a hidden,
auto-retractable needle, 360 degree connector, and smallest
one-click, all-in-one inserter.
The core of the Spring Universal Infusion Set is the proprietary
Detach-Detect mechanism. In the case the base of the infusion set
detaches from the user's body, a blocking mechanism is triggered
which, in turn, creates an occlusion. This evokes an occlusion
alarm in an insulin pump. This unique feature enables exceptional
reliability for continuously controlled and monitored insulin
delivery, providing additional safety and peace of mind -
especially for athletes and the parents of pediatric patients.
About D. Medical
D. Medical is a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery. D.
Medical has developed durable and semi-disposable insulin pumps,
which continuously infuse insulin into a patient's body, using its
proprietary spring-based delivery technology. D. Medical believes
that its spring-based delivery mechanism is cost-effective compared
to the motor and gear train mechanisms that drive competitive
insulin pumps and also allows it to incorporate certain
advantageous functions and design features in its insulin pumps. D.
Medical has also developed an infusion set for insulin pumps and is
focusing its research and development efforts on the development of
next generation insulin pumps and a device that will combine a
continuous glucose monitoring system and an insulin pump on the
same patch. For more information, please visit
http://www.dmedicalindustries.com (corporate) and
http://www.springnow.com (healthcare professionals, patients and
care givers).
Forward-Looking Statements
This press release contains forward-looking statements (as
defined by the Israeli Securities Law, 1968, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended) that involve risks and
uncertainties. These statements include, forecasts, goals,
uncertainties and assumptions and relate, inter alia, to D.
Medical's future expectations in connection with its level of sales
and cost of sales, manufacturing volumes, the cost-effectiveness of
its spring-based design, target markets, regulatory approvals and
timing of markets penetration. The forward-looking statements are
based on D. Medical's current expectations and beliefs which are
based on, among other things, its analysis of publicly available
information and market research reports. All forward-looking
statements are subject to certain risks, uncertainties and
assumptions that could cause actual results to differ materially
from those described in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the impact of
general economic conditions, competitive products, product demand,
product performance, the performance of D. Medical's contract
manufacturer and distributors, regulatory trends and approvals and
healthcare reform legislation. If one or more of these risks and/or
uncertainties materialize, or if the underlying assumptions prove
to be incorrect, D. Medical's actual results, performance or
achievements could differ materially from those expressed in, or
implied by, any such forward-looking statements or results which
are based upon such assumptions. No assurances can be given that
any of the events anticipated by the forward-looking statements
will transpire or occur, or of any of them will transpire or occur,
what impact it will have on D. Medical's results of operations or
financial condition. D. Medicals does not undertake to update any
forward-looking statements.
Contacts: Company Contact: D. Medical Industries Ltd. Amir
Loberman Chief Financial Officer +972-73-2507135 info@springnow.com
North American Investor Contact: D. Medical Industries Ltd. Stephen
Kilmer 212.618.6347 or M: 905-906-6908
stephen@dmedicalindustries.com www.dmedicalindustries.com Israeli
Investor Relations: Iris Lubitch 972-775538007
Iris@EffectiveIR.co.il
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024